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Between 2007 and 2008, the Mozambique Ministry of Health conducted an assessment of human
immunodeficiency virus drug resistance (HIVDR) using World Health Organization (WHO) methods in
a cohort of children initiating antiretroviral therapy (ART) at the main pediatric ART referral center in
Mozambique. It was shown that prior to ART initiation 5.4% of children had HIVDR that was associated
with nevirapine perinatal exposure (P < .001). Twelve months after ART initiation, 77% had viral load
suppression (<1000 copies/mL), exceeding the WHO target of ‡70%; 10.3% had HIVDR at 12 months. Baseline
HIVDR (P5 .04), maternal prevention of mother-to-child transmission (P5 .02), and estimated days of missed
medication (P 5 .03) predicted HIVDR at 12 months. As efforts to eliminate pediatric AIDS are intensified,
implementation of ritonavir-boosted protease inhibitor regimens in children with prevention of mother-
to-child transmission exposure may reduce risk of virological failure in our setting.
The rapid scale-up of antiretroviral therapy (ART) has
dramatically reduced human immunodeficiency virus
(HIV)–related morbidity and mortality [1–7]. In large
part, successful ART scale-up in resource-limited set-
tings can be attributed to the use of a public health
approach where standardized treatment guidelines are
adapted to local circumstances and implemented on
a large scale. Despite impressive gains in ART coverage
in recent years, as of December 2010 only 23% of
HIV-infected children aged ,15 years in need of therapy
were receiving it [8].
Scale-up of ART will inevitably lead to the emergence
of some HIV drug resistance (HIVDR) [9, 10], which
is of particular concern in the pediatric population.
Although increased prevention of mother-to-child
transmission (PMTCT) coverage will reduce incident
infection, it is likely that children who are infected with
HIV despite PMTCT will have some degree of HIVDR.
Additionally, limited access to routine viral load (VL)
monitoring, limited availability of pediatric drugs for
second-line therapy, and unique challenges related to
pediatric ART adherence raise concerns about HIVDR
in children receiving ART [11–13].
Mozambique has an estimated HIV prevalence of
11.5% [14], representing approximately 1.4 million
adults and 100 000 children. ART scale-up began in
2003, and as of October 2010, 211 000 adults and 16 800
children were receiving ART. ART coverage of adults
and children in need of therapy is estimated to be 40%
and 27%, respectively [15]. In Mozambique, ART is
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provided following a population-based model of care. Prior
to December 2008, HIV-infected children with World Health
Organization (WHO) clinical stage III or IV disease (regardless
of CD4 cell count) or children with CD4 percentage ,20%
(for children aged ,18 months) or ,15% (for children aged
.18 months), regardless of clinical stage, were eligible to initiate
ART [16]. After December 2008, all infants aged,12 months
with WHO clinical stage III or IV disease (regardless of CD4 cell
count) or children with CD4 percentage ,20% (for children
aged ,36 months) or ,15% (for children aged .36 months),
regardless of clinical stage, were eligible to initiate ART [17].
First-line pediatric ART consists of zidovudine (ZDV) or
stavudine (d4T) in combination with lamivudine (3TC) and
either nevirapine (NVP) or efavirenz (EFV). The vast majority
of children receive d4T and NVP–containing regimens in the
form of pediatric fixed-dose combinations (from December
2007 onward), with ZDV and EFV reserved for cases of
toxicity. Children aged ,3 years receiving concomitant tuber-
culosis treatment are prescribed a triple nucleoside analogue
combination: ZDV, 3TC, and abacavir. Infants infected with
HIV despite mother-to-child prophylaxis receive a ritonavir-
boosted protease inhibitor (PI)–based regimen, lopinavir/
ritonavir (LPV/r) in combination with ZDV and 3TC.
Acknowledging the importance of HIVDR surveillance and
the need to optimize pediatric ART delivery, Mozambique’s
national HIVDR working group piloted the WHO’s generic
protocol to estimate acquired drug resistance in children initi-
ating first-line ART and to assess associated factors at sentinel
ART clinics. The methods described in the pediatric generic
protocol are consistent with the WHO generic protocol for adult
populations [18]. This standardized, minimum-resource
method evaluates prevalence of HIVDR prevention (defined as
VL suppression with HIV RNA ,1000 copies/mL 12 months
after ART initiation) during the first year of treatment in cohorts
of children starting first-line ART at sentinel clinics.
Specifically, the goals of this survey were to (1) estimate the
proportion of the pediatric population achieving HIVDR pre-
vention 12 months after starting first-line ART; (2) describe
specific HIVDR mutations and mutation patterns among pe-
diatric patients not achieving VL suppression; and (3) identify
patient and program factors associated with HIVDR emergence.
Results from this pilot and from future surveys at clinics chosen
to be representative of different models of pediatric ART treat-
ment will support optimization of pediatric ART delivery and
care in Mozambique.
METHODS
Survey Setting and Population
This survey was conducted between October 2007 and June 2008
at the Pediatric Day Hospital (HDP), Maputo Central Hospital,
Maputo, Mozambique. HDP is the main pediatric ART referral
center in Mozambique and has been operational since 1994.
At the time of the survey, there were .4000 HIV-infected
children in care and .1000 receiving ART.
Survey Design and Procedures
The survey protocol was based on the WHO generic protocol
for assessment of acquired HIVDR in the pediatric population.
This protocol is similar to the generic adult protocol [18] with
appropriate pediatric adaptations including evaluation of pre-
vious PMTCT exposures of mother and child as well as
appropriate weight-based dosing and availability of pediatric
ART formulations. Per WHO guidance, an effective sample
size of 96 permits estimation of clinic-level HIVDR pre-
vention 12 months after initiation of ART [18]. The survey
protocol received approval from Mozambique’s National
Health Bioethics Committee and the Ministry of Health.
Children aged #15 years initiating first-line ART and those
whose legal guardians consented to participation were included,
regardless of previous PMTCT exposure. Exclusion criteria in-
cluded children who had previously initiated first-line ART
at HDP and stopped; patients transferring from another ART
clinic on a standard first-line ART regimen; and those children
whose guardians declined informed consent. At initiation of
ART (baseline), minimal demographic data including previous
antiretroviral (ARV) exposure and specimens for HIVDR gen-
otyping were obtained. At 12 months after ART initiation, blood
for VL testing was collected from all children alive and still on
ART. Specimens with VL .1000 copies were then genotyped.
Twelve months after ART initiation, the following survey
endpoints were assigned: still on first-line ART, lost to follow-up
(LTFU), died, transferred to another ART clinic, or stopped
ART; transfers out and deaths were censored from analyses.
Survey outcomes included the following:
1. HIVDR prevention: alive and on first-line ART at
12 months with a VL ,1000 copies/mL. The WHO target for
HIVDR prevention is $70% VL suppression at each clinic.
2. Possible HIVDR: alive and on first-line ART at 12 months
but with VL $1000 copies/mL and no detected HIVDR; and
children LTFU or who stopped ART.
3. Detected HIVDR: alive and on first-line ART at
12 months, with VL $1000 copies/mL and HIVDR mutations
generating a high-, intermediate-, or low-level resistance
classification to ARVs per the Stanford HIVDR algorithm
(HIVdb program version 6.0.11) [19].
Adherence to ART
Two population-level surrogate measures of adherence were
used. The estimated number of days over the entire 12-month
period where each child was without ART, if the regimen
had been taken according to prescription, was calculated and
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expressed as a percentage. Additionally, on-time appointment
keeping was used as a surrogate for adherence to ART. On-time
appointment keeping was defined as attending appointments
within 7 days of the scheduled appointment and was expressed
as a percentage of total scheduled appointments during the first
year of ART.
Clinical and Routine Laboratory Assessments
All clinical and demographic data were abstracted from ex-
isting medical records. CD4 cell counts were performed at
baseline and at 6-month intervals per clinic routine. CD4
T-lymphocyte counts were performed using the FACSCalibur
flow cytometer (Becton Dickinson, San Jose, California). At
endpoint, plasma VL was quantified using Versan HIV RNA
Assay 3.0 (Siemens Medical Solutions, Tarrytown, New York).
HIVDR testing was performed at baseline and after 12 months
of ART in patients with VL .1000 copies/mL. Dried blood
spots and plasma were used for HIVDR genotyping at baseline
and at endpoints, respectively.
HIV Genotypic Resistance Analysis
HIVDR testing was performed at the National HIV and Retro-
virology Laboratories, Public Health Agency, Ottawa, Canada.
Complete protease and part of reverse transcriptase regions
were sequenced using previously described procedures [20].
Sequencing was performed using the Big-Dye Terminator Cycle
Sequencing Kit (Applied Biosystems, Carlsbad, California). The
neighbor-joining distance matrix method was used to assign
HIV subtype based on the pol gene [21]; all subtypes were
confirmed using the REGA HIV subtyping tool (http://www.
bioafrica.net/rega-genotype/html/subtypinghiv.html).
Statistical Analysis
Data were analyzed using STATA 11 software (StataCorp,
College Station, Texas). Associations between categorical
variables were determined using Pearson’s v2 test and
Fisher’s exact test. Numeric variables were compared by medians
using the Mann–Whitney test. To control for different risk
factors associated with outcomes, including baseline HIVDR,
logistic regression was performed. Only factors with significance
,20% on univariate analysis were included in the multivar-
iate model; all factors found not to be statistically significant
were excluded. Age and sex were included as control variables.
RESULTS
Between October 2007 and June 2008, 119 eligible children
between 0 months and 13 years of age consecutively initi-
ating first-line ART at HDP were enrolled in the survey. Fifty
percent of children were ,18 months of age, 90% had ad-
vanced disease (WHO clinical stages III and IV), and 48% were
severely immunocompromised.
HIVDR at Baseline
Baseline demographic data are presented in Table 1. All children
were initiated on a standard first-line ART regimen as defined
by national ART guidelines: ZDV, 3TC, and NVP for 62 of
119 (52.1%) children; d4T, 3TC, and NVP for 55 of 119 (46.2%)
children; and d4T, 3TC, and LPV/r for 2 of 119 (1.7%) chil-
dren. Thirteen children reported having received PMTCT
prophylaxis.
Baseline genotypes were available for 112 of 119 (94.1%)
children, with HIVDR-associated mutations observed in 6 of
112 (5.4%): 5 (4.5%) had nonnucleoside reverse transcriptase
inhibitor (NNRTI)–related mutations, of whom 1 (0.9%) had
both NNRTI and nucleoside reverse transcriptase inhibitor
(NRTI) mutations and 1 (0.9%) had NRTI mutations only.
Four of the 13 (30.7%) children with maternal or child PMTCT
exposure had baseline HIVDR (Supplementary Table 1). Peri-
natal exposure to NVP predicted baseline resistance (odds
ratio [OR], 35.7 [95% confidence interval {CI}, 4.1–310.6];
P , .001). HIV subtype distribution was as follows: 98%
subtype C, 1% subtype D, and 1% C/D recombinant.
HIVDR Outcomes at 12 Months
Twelve months after ART initiation, 101 (84.9%) children were
alive and on ART, 6 (5.0%) died, 12 (10.1%) were LTFU, none
Table 1. Baseline Characteristics of a Cohort of 119 Children
Initiating Antiretroviral Therapy at Pediatric Day Hospital, Maputo
Central Hospital, Mozambique (2007–2008)
Characteristic No. (%)
Age (months)
Minimum–maximum 3.7–167.6
Median (IQR) 25.2 (15.2–70.8)
0–18 41 (34.5)
19–59 45 (37.8)
$60 33 (27.7)
Area of residence
Rural 15 (12.6)
Suburban 79 (66.4)
Urban 25 (21.0)
WHO clinical staging
I 2 (1.7)
II 6 (5.0)
III 54 (45.4)
IV 56 (47.1)
Unknown 1 (0.8%)
CD4 percentage
,5 10 (8.4)
5–15 56 (47.1)
$15 45 (37.8)
Unknown 8 (6.7)
Abbreviations: IQR, interquartile range; WHO, World Health Organization.
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stopped ART, no child transferred care to a different site, and
none switched from an NNRTI- to a PI-based regimen. The
few children who initiated boosted PI-based ART remained
on the same regimen. Intraclass substitutions for toxicity or
side effects were not assessed in this survey. At 12 months, VL
data were available for 96% (97 of 101) of the children.
HIVDR Prevention
By excluding death and transfer out from the analysis and by
treating LTFU as having virological failure, 87 of 113 (77.0%)
children initiating first-line ART achieved HIVDR prevention
at 12 months. In an on-treatment analysis of children alive
and on ART at 12 months, 89.7% (87 of 97) of children with
available VL test results at 12 months had VL,1000 copies/mL.
Possible HIVDR
By excluding death and transfer out from the analysis and by
treating LTFU as having virological failure, 10.6% (12 of 113)
children had possible HIVDR. In an on-treatment analysis,
possible HIVDR was 0% because none of the children had VL
.1000 copies/mL and no detected HIVDR.
Detected HIVDR
By excluding death and transfer out from the analysis and by
treating LTFU as having virological failure, 8.8% (10 of 113) had
detected HIVDR-associated mutations. In an on-treatment
analysis, 10.3% (10 of 97) of the children with VL testing
available at 12 months had detected HIVDR.
At 12 months, overall 8.8% (10 of 113) and 7.9% (9 of 113)
of specimens had resistance mutations associated with NRTI
and NNRTI, respectively. The most frequently observed muta-
tions at endpoint were Y181C (6.1%) and M184V (7.9%). The
K65R mutation was observed in 2 children (1.8%). Dual NRTI
and NNRTI class resistance was present in 8.0% (9 of 113) of
the specimens (Supplementary Table 1).
Table 2. Risk Factors for Development of HIV Drug Resistance 12 Months After Initiation of Antiretroviral Therapy
Risk Factor
Patients With
VL .1000 Copies/mL
and Detected HIVDR
Mutations at 12 Months (%)
Patients With VL
,1000 Copies/mL
at 12 Months (%)
Univariate Analysis Multivariate Analysis
OR (95% CI) P Valuea P Valueb OR (95% CI ) P Valuec
No. 10 87
Males 6 (60.0%) 37 (42.5%) 2.03 (.53–7.81) .292 .236 2.00 (.41–9.73) .391
Age at ART initiation
(months)
1.0 (.98–1.02) .997
Median (IQR) 19.1 (6.2–30.0) 33.6 (16.7–80.9) .145
Mother exposed to
ARV for PMTCT
4 (40.0%) 10 (11.5%) 5.13 (1.17–22.54) .016 .035 6.41 (1.21–33.88) .029
Newborn exposed to
ARV for PMTCT
3 (30.0%) 7 (8.1%) 4.90 (.98–24.38) .031 .065 . .
Resistance at ART
initiation
2 (20.0%) 2 (2.3%) 10.65 (1.20–94.18) .008 .052 47.0 (1.05–2111.78) .047
CD4 (%) at ART
initiationd
10 81
Median (IQR) 9.1 (6.0–13.5) 14.5 (12.0–18.0) .022 . .
WHO stage at ART
initiation
.317 1.000 . .
I, II 0 (0.0%) 8 (9.2%) .
III, IV 10 (100.0%) 79 (90.8%) .
Estimated days of
missed
medication, %
Median (IQR) 6.8 (0.0–12.7) 0.0 (0.0–4.3) .041 1.07 (1.01–1.14) .033
Missing clinical
consultations, %
. .
Median (IQR) 7.4 (0.0–15.4) 20.0 (7.1–23.1) .076
Abbreviations: ART, antiretroviral therapy; ARV, antiretroviral; CI, confidence interval; HIV, human immunodeficiency virus; HIVDR, HIV drug resistance; IQR, interquartile
range; OR, odds ratio; PMTCT, prevention of mother-to-child transmission; VL, viral load; WHO, World Health Organization.
a P value for Pearson’s v2 categorical variables/Kruskal–Wallis median.
b P value for Fisher’s exact v2.
c P value for adjusted odds ratio.
d Only 81 of 87 of patients without resistant mutations at 12 months had CD4 percentage measured.
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Age at ART initiation, mother and newborn ARV exposure
for PMTCT, adherence (as determined by missing days of
medication), and CD4 percentage were associated with HIVDR
at 12 months of ART in univariate analyses. In the multivariate
analysis, factors that remained significant included baseline
HIVDR (OR, 47.0 [95% CI, 1.05–2111.78]; P 5 .04), maternal
exposure to ARVs for PMTCT (OR, 6.4 [95% CI, 1.21–33.8];
P 5 .02), and estimated days of missed medication (OR, 1.07
[95% CI, 1.01–1.14]; P 5 .03 (Table 2). During the survey no
ART stockouts were documented, and all children were pre-
scribed and maintained on standard, appropriately weight-based
first-line regimens (Table 2).
DISCUSSION
Rapid ART scale-up in Mozambique began in 2003. As of
2011, .16 000 children were receiving ART in the national
program following a standard public health approach. In-
dividual HIVDR genotyping is not routinely available nor
recommended; thus, understanding factors associated with
successful VL suppression and the prevention of HIVDR
in children receiving ART is essential for good program
management.
Overall, low levels of HIVDR were observed among children
about to initiate ART; however, 4.5% of children did have
NNRTI mutations that predicted virologic failure at 12 months.
Not unexpectedly, 5 of 6 children with baseline NNRTI re-
sistance had perinatal exposure to NVP (P 5 .04). Perinatal
exposure to NVP was the only factor significantly associated
with baseline HIVDR (OR, 35.7 [95% CI, 4.10–310.61];
P , .001). This observation has been reported in other
studies [22–24], in particular, when NVP is administered as
a single-dose regimen, which was the case for one-third of
the PMTCT-exposed children in our survey.
Findings from this pilot survey show that 12 months after
ART initiation, prevention of HIVDR was observed in 77% of
children initiating first-line ART during the survey period. Re-
sults exceeded the WHO-suggested target of $70% [19]. This
rate of virological suppression during the first year of ART is
similar to reports from other settings [25–29].
Overall, 8.8% (10 of 113) of the children initiating ART had
detected HIVDR-associated mutations at 12 months. Dual class
resistance, including combined NRTI and NNRTI, was present
in 9 of 113 (7.9%) children. No PI mutations were detected,
which reflects the very low use of PIs in this population. The
most frequently detected mutations were M184V and Y181C.
The mutation M184V selected by the use of 3TC has been found
in similar settings in both adults and children in which 3TC is
included in the first-line ART. The NNRTI mutation Y181C is
frequently found in patients on NVP-containing ART regimens
and has been found in infants exposed to NVP single-dose
PMTCT for HIV subtypes B and C. The K65R mutation has
been found in patients taking d4T and was present in 2 of
96 (1.8%) children. Similar resistance patterns have been re-
ported among patients failing the same first-line regimens used
in this cohort [11, 12, 29–33]; resistance rates reported were
higher than in our cohort, but comparisons are unreliable due
to significantly different methods.
Age at ART initiation, perinatal ARV exposure of the
mother and newborn, adherence (determined by missing
days of medication), HIVDR at ART initiation, and CD4
percentage were associated with HIVDR at 12 months of
ART in univariate analyses. However, in the multivariate
analysis, only maternal PMTCT exposure, adherence, and
baseline HIVDR were associated with HIVDR at 12 months
of ART. In this survey, all children failing ART had detected
HIVDR-associated mutations, suggesting that in this cohort
adherence support and counseling were probably effective.
Recent results of the P1060 study [34] showed that NVP
for PMTCT and treatment with a first-line ART regimen, in-
cluding a ritonavir-boosted PI, was significantly more effective
in treating infants than NNRTI-containing regimens. This
has led to a modification of pediatric ART initiation guidelines,
which now recommend the use of a PI as first-line therapy.
As efforts to eliminate pediatric AIDS are intensified, im-
plementation of ritonavir-boosted PI regimens in children with
PMTCT exposure may reduce the risk of virological failure in
our setting.
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